Search Result for : Medicines

The Dollar Business Bureau Indian Pharma exports to the US may increase in 2017-18 despite pricing pressure and stiff competition. A report released by Care Ratings said that $50 billion worth of drugs are expected to become 'off-patent' in the current year giving hope to the Indian Pharma export market. "The pharma export volumes from India to US, however, are expected to rise. This will be backed by about $55 billion expected sales gain to generics drugs on account of branded drugs going off patent during 2017-19 which will create an opportunity for CRAMS segment. We expect growth rate for CRAMS (Contract Research and Manufacturing Services) to be higher compared to average growth rate of the industry. These factors are likely to support pharma exports from India," ...

Sneha Gilada The pharma bigwigs, after the government recently imposed a cap on stent prices, are in for another rough ride as PM Modi seeks to make prescription of cheap generic drugs binding on doctors. Speaking at the inauguration ceremony of a charitable hospital in Surat on April 17, Narendra Modi vowed to take on the mantle of making healthcare affordable to the Indian middle class and poor. In his speech, he averred that the health policy was being revamped after a gap of 15 years. The last time it was updated was back in 2002. The new health policy lays special emphasis on the pricing of drugs included in the National List of Essential Medicines (NLEM), along with the timely revision of the list. "Price control ...

The Dollar Business Bureau India is ready to make an investment of $10 billion in Bangladesh for the development of its sectors such as infrastructure, power and energy, logistics, education, medical, rail, road and waterways and medicine, said Bangladesh Prime Minister Sheikh Hasina after returning from a four-day tour visit to India.   The PM also informed that Indian government will be extending a loan of $5 billion, out of which $500 million will be used for consolidating the Bangladesh military. The monetary assistance will be specifically used for training the military personnel to ensure peace in border areas, and joint patrols and drills in international sea areas. The amount will also be invested in purchasing military equipment. "The offers of investment and ...

The Dollar Business Bureau Dr Reddy's Laboratories has entered into an agreement with US-based biotechnology firm Amgen to sell its three drugs meant for heart and cancer patients in India. Terming it as a “strategic collaboration”, Dr Reddy’s said that it will undertake a full range of regulatory and commercial services to seek approval and launch the three medicines— Kyprolis, Blincyto and Repatha in the Indian market. “We are excited about our strategic collaboration with an innovation powerhouse like Amgen and look forward to making their innovative medicines accessible to Indian patients. Addressing significant unmet needs of patients in oncology and cardiovascular are key areas in India and therefore, a priority for us at Dr Redy's," said Alok Sonig, Executive Vice-President and Head of ...